The short version of cjc-1295 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
=== Neurotoxicity === Dextromethorphan was once thought to cause Olney's lesions when administered intravenously; however, this was later proven inconclusive, due to lack of research on humans. Tests were performed on rats, giving them 50 mg or more every day for as long as a month. Neurotoxic changes, including vacuolation, have been observed in posterior cingulate and retrosplenial cortices of rats administered other NMDA receptor antagonists such as PCP, but not with dextromethorphan.
== Structure-activity relationships == There is a rather large homology in structure between arenobufagin and cardiac glycosides. Cardiac glycosides are natural compounds found in plants which cause inactivation of the sodium potassium pump like arenobufagin. The specific steroidic structure binds to the pump in a way it inhibits the process of pumping potassium into the cell and sodium out of the cell. The exact way of binding to the Na-K-Pump is not yet documented.
=== Dyes === Primary aromatic amines are used as a starting material for the manufacture of azo dyes. It reacts with nitrous acid to form diazonium salt, which can undergo coupling reaction to form an azo compound. As azo-compounds are highly coloured, they are widely used in dyeing industries, such as:
The eighth generation was released for the Japanese domestic market in June 1994 with front-wheel drive. The saloon version was again sold as the "Mazda Protegé" in North America, as the Mazda Artis in some South American markets, as the "Mazda Étude" in South Africa and as Mazda Allegro in Colombia. Originally there was a three-door coupé (323C/Familia Neo) available, but after sluggish sales, a hatchback version based on the facelifted Familia saloon replaced it. This generation grew considerably, with the four-door saloon's wheelbase only 5 millimetres short of the then-current Mazda 626, a mid-size car. The car was not originally offered with a 1.3-litre engine in Japan, with the lineup beginning with the bigger 1.5-litre. To close this gap in the lineup, the BG hatchback with the 1.3-litre engine was kept available until October 1996, when the new hatchback model was introduced (323P) and the smaller engine was made available. An unusual JDM station wagon model appeared in September 1994, with the discontinuation of the 1985-generation station wagon. The Mazda Familia Van offered after this year was a rebadged Nissan AD/Wingroad/Sunny California, which was essentially the station wagon version of the Nissan Sunny/Sentra/Pulsar (N14). A new model appeared in the same month, when a lean-burn version called the GS-L arrived: its Z5-DEL engine produces 94 PS (69 kW), three down on the regular Z5-DE, but gas mileage improved by ten to fifteen percent. Another loan was the 1.7-litre intercooled turbo-diesel engine purchased from Isuzu for use in saloons since October 1994.
Sources: en.wikipedia.org
== Overdose == There have been cases of death with DMT. In terms of extrapolated human lethal dose based on animal studies and human case reports, the lethal dose of DMT relative to a typical recreational dose is estimated to be 50-fold in the case of oral DMT (as ayahuasca).
Produced by Peter Goodchild, directed by Bryn Higgins (the mock-documentary looked like an episode of Casualty, which he would later direct), made by Stone City Films 14 July Russian Roulette, about the early warning system in operation over Russia; 25 January 1995 over the Barents Sea, an object is detected, which at first looks like a missile, but after 8 minutes falls into the sea - it was a Norwegian rocket, and the Russians had been notified of the launch weeks before, but had not told their radar units; Bruce G. Blair, a nuclear security writer from the Brookings Institution; Colonel Robert Bykov of the Strategic Rocket Forces of Russia; Alexander Pikayev of the State Duma Defence Committee; Admiral Stansfield Turner of the United States Navy; General Eugene E.
In biochemistry, cyclotides are small, disulfide-rich peptides isolated from plants. Typically containing 28–37 amino acids, they are characterized by their head-to-tail cyclised peptide backbone and the interlocking arrangement of their three disulfide bonds. These combined features have been termed the cyclic cystine knot (CCK) motif. To date, over 100 cyclotides have been isolated and characterized from species of the families Rubiaceae, Violaceae, and Cucurbitaceae. Cyclotides have also been identified in agriculturally important families such as the Fabaceae and Poaceae.
== Medical use == Silicone gel sheeting is the gold-standard and non-invasive treatment for hypertrophic and keloid scars. During skin injury repair, dermal cells proliferate and migrate from the skin tissue to the wound, producing collagen and causing contraction of the placement dermis. These scars are proliferative due to chronic inflammation and overproduction of abnormal collagen. Common clinical presentations of these scars are raised, thickened, red, or dark-colored. Patients may also experience pain and itching. Hypertrophic scars are elevated scars that remain in the region of the original lesion following mechanical traumas, burns, and necrotizing infections. These scars typically develop in locations under tension, such as shoulders, ankles, knees, and the neck. Hypertrophic scars are generally confined to the boundaries of the original wound and tend to diminish over time.
Histology image: 08008loa – Histology Learning System at Boston University Atlas image: eye_1 at the University of Michigan Health System—"Sagittal Section Through the Eyeball" MedlinePlus Encyclopedia: 002295
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.